Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 116
- Registration Number
- NCT00629616
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Hopital Dupuytren, Limoges Cedex, France
🇫🇷Centre Eugene Marquis, Rennes, France
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT00612560
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00588003
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT00573755
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Mothaffar Rimawi
- Target Recruit Count
- 72
- Registration Number
- NCT00570323
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00562458
Patient's Anastrozole Compliance to Therapy Programme
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4923
- Registration Number
- NCT00555867
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00555477
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00544986
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 870
- Registration Number
- NCT00543127
- Locations
- 🇪🇸
Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸Hospital Lluís Alcanyis, Xátiva, Valencia, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.